Finally, our findings support modifications to the standard of care for CK-MDS patients to include routine genetic sequencing of TP53. These mutations modify risk assessment even in CK-MDS patients traditionally considered to have the greatest disease risk. The gene discussed is TP53; the disease is myelodysplastic syndrome.